Tuesday 11 May 2021
- Advertisement -

Serum Institute fixes Covishield price at Rs 600/dose for private hospitals, Rs 400 for state govts

The Serum Institute of India (SII) has announced that it will price its Covishield vaccine at Rs 600 per dose for private hospitals and Rs 400 per dose for state governments

The Serum Institute of India (SII) has announced that it will price its Covishield vaccine at Rs 600 per dose for private hospitals and Rs 400 per dose for state governments.

In a statement, SII has said, “For the next two months, we will address the limited capacity by scaling up the vaccine production. Going ahead, 50% of our capacities will be served to the Government of India’s vaccination program, and the remaining 50% of the capacity will be for the state governments and private hospitals.”

Comparing the prices with the other vaccines in the world, SII has stated that while American vaccines are priced at Rs 1,500, Russian and Chinese vaccines would cost Rs 750 per dose, making Covishield a cheaper option.

However, the vaccine price will remain at Rs 150 per dose for use by the union government.

In an order earlier this week, the union government said all above 18 years of age are eligible for vaccination from 1 May. As it liberalised the vaccination drive, the government allowed states, private hospitals and industrial establishments to procure the vaccine doses directly from manufacturers.

Of the 12.76 crore vaccine doses administered so far, the Covishield comprises over 90% of the vaccine doses, according to government data on 21 April. Of this, 15 states and union territories have only given Covishield.

Meanwhile, Prime Minister Narendra Modi on 20 April urged India’s vaccine manufacturers to continuously scale up their production capacity to vaccinate all Indians in the shortest possible time. India on Wednesday recorded nearly 3 lakh fresh cases in its biggest jump so far. The death toll has also gone up by over 2,000 in a day.

Interacting with vaccine manufacturers from across the country via video conferencing, Modi said the private sector will play an even more active role in the vaccination drive in the coming days and that this will require better coordination between hospitals and the industry.

In another significant move, the union government has approved advance funds of Rs 3,000 crore for the SII and Rs 1,500 crore for Bharat Biotech, which is producing the Covaxin shots.

Meanwhile, Johnson & Johnson has applied to India’s drug regulator for permission to conduct the phase-3 clinical trial of its single-dose Covid-19 vaccine in India while also seeking an import licence.

They said the company has sought an early meeting of the subject expert committee on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) to take a decision on its application.

Publishing partner: Uprising

Sirf News needs to recruit journalists in large numbers to increase the volume of news stories. Please help us pay them by donating. Click on the button below to contribute.

Sirf News is now on Telegram as well. Click on the button below to join our channel (@sirfnewsdotcom) and stay updated with our unique approach to news

Disclaimer: If the footer of a report says the story is syndicated, it implies that it is a report picked automatically by the RSS feed of the media house mentioned. Such content is not edited by the Sirf News’ team of editors. We have begun this section to benefit our readers with more stories from India and across the world at a one-stop destination. The copyright of such a story belongs to the media house named. Sirf News' system picked it from the mentioned media house's RSS feed available in the public domain.

Related Articles

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Stay Connected

- Advertisement -

Latest Articles

Translate »
%d bloggers like this: